A new mom shares how the recently approved two-week postpartum depression drug was a game-changer to combat a notably common condition during a tender phase of life. The post I Took the New Postpartum ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Biogen and Sage Therapeutics' zuranolone has become the first oral drug to be approved by the FDA for post-partum depression (PPD), but the US regulator turned down a request for wider use in the ...

Experts highlight the potential of under-utilised treatments like monoamine oxidase inhibitors while examining emerging ...